Efficacy of different schedules of HDR brachytherapy in concurrent chemoradiotherapy was evaluated. The study compared the effectiveness of the two HDR brachytherapy schedules which have the same Biological Effective Dose (BED) in locally advanced cervical carcinoma that was treated with concurrent chemoradiotherapy. Included in the study were 377 randomly selected patients with advanced carcinoma of the cervix uteri who were treated during the period [2004][2005][2006]. Patients were divided into Group I: 7.2 Gy × 3 fractions and Group II: 6 Gy × 4 fractions. With a median follow-up time of 35 months, local control, disease-free survival and overall survival rates were 80.8%, 63.4%, 98.8% in group I and 86.7%, 63.8%, 97.3% in group II, respectively. There was no statistical significance in terms of local control, disease-free survival, overall survival and complication rates between the two treatment schedules which could be observed. Seven patients in group I developed acute grade 2-4 GI toxicities and two patients in group II. In GU toxicities, there were three patients in group I and three patients in group II who developed grade 2-4 toxicities. In late toxicity, no patient developed grade 3-4 GU toxicities in group I while two patients developed grade 3-4 GU toxicities in group II. In GI toxicities, there were five and six patients in group I and group II, respectively, who developed grade 3-4 severity. Both HDR schedules seem to be safe and effective for the treatment of locally advanced cervical cancer.
INTRODUCTION
Radiotherapeutic treatment of cervical cancer has mainly consisted of External Beam Radiotherapy (EBRT) and Intracavitary Brachytherapy (ICBT). The goal of brachytherapy was to augment the dose of a paracentral point to the dose of 75-95 Gy.
1) Doses of ICBT were still controversial according to institutional experience but maintained the principles of the International Commission of Radiological Units (ICRU). 2) In ICRU #38, the methods of determining the measurement of bladder and rectal dose points were identified and the limitations of the dosage at these points noted. High-Dose-Rate (HDR) brachytherapy began in 1958 and has become highly developed during the past 30 years. usage was developed utilizing small units which could be applied in many techniques and sites of treatment. The advantages of HDR were rigid immobilization, outpatient treatment, patient convenience, and potential cost savings. 3) In carcinoma of cervix uteri, ICBT with HDR brachytherapy has been administered for many years. The confirmation of meta-analysis showed that there was no difference in efficacies and toxicities between LDR and HDR. 4) Although the usage of HDR brachytherapy in cervical cancer nowadays is agreed without question, the optimal dosage schedule is still controversial. The practical use of HDR brachytherapy varies according to the experiences of individual institutions. The American Brachytherapy Society (ABS) published a recommended dosage schedule of ICBT in cervical cancer in 2001.
5) The recommended dosage of 28-34.8 Gy in 4-6 fractions combined with EBRT 45-50. 4 Gy was considered acceptable. From the guidelines of the Japan Society of Gynecologic Oncology, the Japanese standard schedule (with the dose of 15-23 Gy in 3-4 fractions combined with EBRT 20-50 Gy) has a lower total radiation dose compared with those in the United States. 6) With the standard dose guidelines, the Biological Effective Dose (BED) at point A (α/β = 10) was 107-108 Gy 10 in ABS recommendations and 60-83 Gy 10 in the Japanese schedule. So, the optimal HDR-fractionation schedule for the treatment of cervical cancer remained under debate. Various fractionation schemes have been used "experimentally" in search of the "optimal" technique. 7) Presently, completed data has confirmed that the results of combined modality therapy (especially with a platinum-containing regimen) can lead to a prolonged time before disease recurrence and an increase in overall survival in locally advanced cervical cancer. [8] [9] [10] However, little comparative study between HDR dose schedules has been performed in locally advanced cervical cancer treated with concurrent chemoradiotherapy. This study was performed to evaluate the efficacy of a different schedule of HDR brachytherapy in concurrent chemoradiotherapy. Two HDR brachytherapy schedules were compared utilizing the same Biological Effective Dose (BED) to point A (α/β = 10) for locally advanced cervical carcinoma treated with concurrent chemoradiotherapy.
MATERIALS AND METHODS

Patient characteristics
After approval from the ethics committee, patients with locally advanced carcinoma of the cervix uteri who were treated from 2004 to 2006 were included in the study. All patients had the following characteristics: stage IIB-IVA by FIGO staging, ages 18-70 years, histology proven carcinoma of cervix uteri, Estern Cooperative Oncology Group (ECOG) performance status scale 0-1, no uncontrolled medical conditions, no previous pelvic surgery or irradiation and had signed the consent form for treatment protocol. Patients who had stage IVB (metastatic disease), allergy were excluded from the study due to their different management.
Radiation techniques
In External Beam Radiotherapy (EBRT), 6-10 MV photons by PRIMUS linear accelerators were used to treat the whole pelvis. The daily fraction of 2 Gy, five days per week was used to a dose of 50 Gy. Central shielding was applied after 40 Gy regardless of stage. Parametrial boost was used to build up the dose of parametrium to 56 Gy. All patients were treated with concurrent chemoradiotherapy with cisplatin (40 mg/m2 weekly, totally 6 cycles) or mitomycin-C (10 mg/m2 wk 1 and wk 6).
The first ICBT was started at the fourth week of radiation therapy. The Fletcher-Suit applicator (Asia-Pacific version) was used in this treatment. In cases of extensive vaginal involvement, intra-vaginal cylinders were used in tandem to treat the primary lesion and vaginal extension. Patients were prospectively randomized into two treatment schedules as follows:
Application of ICBT was performed on an outpatient basis with non-narcotic analgesics. For ICBT simulation, orthogonal films of antero-posterior and lateral views were taken with the applicators inserted, and the position of point A, bladder and rectal points were defined according to the Manchester method and ICRU 38 recommendations.
2) The Linear Quadratic equation was used to calculate the dose to point A which can be calculated as in the following:
Biologically effective dose (BED) to the point A (α/β = 10)
• For whole pelvis RT, the BED 10 was 40(1 + 2/10) = 48 Gy 10 .
• For ICBT group I (21.6 Gy/3 Fr), the BED10 was 21.6(1 + 7.2/10) = 37.2 Gy10.
• For ICBT group II (24 Gy/4 Fr), the BED10 was 24(1 + 6/10) = 38.4 Gy10.
So the total BED 10 of Group I was 85.2 Gy 10 and total BED 10 of group II was 48 + 38.4 = 86.4 Gy 10.
Evaluation
During treatment, patients were appointed to visit the physician to evaluate the toxicities according to the National Cancer Institute; Common Terminology Criteria of adverse event (CTCAE) version 3.0.
11) After the treatment was completed, patients were appointed to visit for a vaginal examination (PV exam) in a follow-up program. A vaginal examination was performed to evaluate the disease status according to the World Health Organization (WHO) criteria. 12) Late toxicities were evaluated according to the Radiation Therapy Oncology Group/ European Organization of Research and Treatment of Cancer (RTOG/EORTC) late toxicity criteria.
13)
Statistical analysis
All data were inputed to SPSS software version 16.0. Tumor response rate, local control, disease-free survival, and Overall survival rates were evaluated between the two groups by the chi-square test. Survival data were calculated by the Kaplan-Meier method and log-rank test to identify any statistical significance between the two groups. 14, 15) 
RESULTS
Patient data
A total of 377 patients were included in this study. Seventeen patients were excluded due to poor compliance. Therefore, 172 Patients were randomized in group I (3 × 7.2 Gy) and the others were randomized in group II (4 × 6 Gy).
The total treatment time was 49 days in both groups. All data are shown in Table 1 .
Treatment results
With the median follow-up time of 35 months, local control, disease-free survival and overall survival rates were 80.8%, 63.4%, 98.8% in group I and 86.7%, 63.8%, 97.3% in group II, respectively. All data of both groups are shown in Table 2 and Fig. 1 .
Analysis was performed on stage IIB and stage IIIB which had the largest populations in these groups. In stage IIB, local control, disease-free survival and overall survival rates were not statistically significant between both groups. In stage IIIB, the tendency was the same except local control rates in stage IIIB (p = 0.065). All data of both groups are shown in Table 3 and Figs. 2-3 .
Toxicity profiles
In the toxicity profiles, seven patients in group I developed acute grade 2-4 gastrointestinal toxicities and two patients in group II. In genitourinary toxicities, there were three patients in group I and three patients in group II who developed grade 2-4 toxicities. No statistical significance could be observed in both GI (0.123) and GU (0.991) toxicities. In late toxicity, no patient in group I developed grade 3-4 GU toxicities while two patients in group II developed grade 3-4 GU toxicities. In GI toxicities, there were six and five patients in group I and group II, respectively, who developed grade 3-4 severity. All data are shown in Tables 4 and 5 .
DISCUSSION
Intracavitary brachytherapy is one component of the radiotherapeutic treatment of carcinoma of cervix uteri. The dosage schedule of brachytherapy in cervical cancer is controversial. High-dose-rate brachytherapies are used worldwide due to the short treatment time, outpatient basis and better radiation protection for hospital staff. 16, 17) The optimal fractionation schedules for HDR brachytherapy are still controversial. Orton et al. showed an increase of morbidity when the dose per fraction at point A was higher than 7 Gy.
18) Petereit et al. reported the results of HDR brachytherapy for cervix cancer using different regimens, however, this study failed to identify the optimal fractionation. 4) Consequently, the study of the fractionation schedule of HDR brachytherapy continues to have a lack of data support. A few studies tried to compare the effectiveness of the different schedules and the results revealed no statistical significance. From the study of Wong et al., the retrospective study reported the results of 7 Gy × 3 fractions versus 6 Gy × 4 fractions in 220 patients. They found that the two HDR fractionation schedules were not a significant prognosticator in the prediction of disease control and complications. 19) In the study from Korea by Nam et al., 46 patients were included in a comparison between 3 Gy × 10 fractions (group A) versus 5 Gy × 5 fractions (group B). The three year disease-specific survival rates of group A and B were 90.5% and 84.9%, respectively (p = 0.64). No difference of the three-year pelvic control was observed (p = 0.92). The incidences of late complications of the rectum or bladder of grade 2 or greater in group A and group B were 23.8% and 9.1%, respectively (p = 0.24). It showed comparable results between the both fractionation schedules. 20) In this study, the results of 7.2 Gy × 3 fractions versus 6 Gy × 4 fractions were comparable. No difference was observed in local control, disease-free survival and overall survival rates in group I versus group II. In stage IIB, local control, disease-free survival and overall survival rates between group I and group II were not statistically significant. In stage IIIB, no statistical significance in all parameters could be observed although there was an improvement of local control in group II (73% vs. 82.2%).
In toxicity profiles, the grade 2-4 acute toxicities were equal between the two groups in terms of gastrointestinal toxicities and genitourinary toxicity aspects. In late toxicities, no statistical significance between the two groups in terms of grade 3-4 gastrointestinal toxicities and genitourinary toxicities was observed. The patient characteristics of both groups were not statistically significant in age, stage and histology. The median treatment time between group I and group II was 49 days which might be one of the factors. For the chemotherapy schedules (cisplatin vs. mitomycin-C), the analysis from our institution was published by 21) Our results showed that the acute side effects are tolerable in patients who are treated with concurrent chemoradiotherapy and late complications were similar. This study showed comparable results of the two fractionation schedules of high-dose-rate brachytherapy in carcinoma of cervix uteri. In stage IIIB, the dose of 4 × 6 Gy was better than the dose of 3 × 7.2 Gy in terms of local control rates but not in disease-free survival and overall survival rates. For the BED10, our study showed the BED10 of 85.2 Gy10 in group I and 86.4 Gy10 in group II which related to the recommended dose of ABS. 5) When compared with the Japanese schedule (Nakano et al.) which showed the BED10 of 62-86 Gy10 in locally advanced disease (stage II/ III), our BED10 was higher. 22) In comparison with our routine schedule reported by Lorvidhaya in 2003, the BED10 was around 87.6 to 102.5 Gy10. Although the BED10 was high, the overall rate of Grades 3 and 4 RTOG complications was 4.2%. 23) Interestingly, the study for Toita et al. showed the cumulative BED 70-80 Gy10 at point A is appropriate for uterine cervical cancer patients treated with a combination of EBRT and HDR-ICBT. Moreover, the study reported patients who received treatment with 86.4 Gy10 at point A suffered both proctitis and enterocolitis which equalled to the BED10 of our study in group II (4 × 6 Gy). 24) However, our study in this group showed only 2.7% of grade 3-4 GI late complications. In summary, our study showed that no statistical significance in terms of local control, disease-free survival, overall survival and complication rates between the two treatment schedules could be observed. The two HDR schedules seem to be safe and effective for the treatment of locally advanced cervical cancer.
